Bio-Rad Laboratories, Inc. Class A Common Stock vs Eni SpA — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Eni SpA trades at $49.51 (market cap $71.48B). The key difference: Eni SpA is far larger — about 8.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Eni SpA pays a 4.94% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | E | |
|---|---|---|
Market Cap | $8.02B | $71.48B |
Sector | Health | Energy |
52-Week High | $339.75 | $57.61 |
52-Week Low | $241.71 | $32.93 |
Enterprise Value | $7.84B | $90.39B |
Dividend Yield | — | 4.94% |
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →